Titlebook: Sandostatin® in the Treatment of Acromegaly; Consensus Round Tabl Steven W. J. Lamberts Conference proceedings 1988 Springer-Verlag, Berlin

encroach

书目名称Sandostatin® in the Treatment of Acromegaly影响因子(影响力)




书目名称Sandostatin® in the Treatment of Acromegaly影响因子(影响力)学科排名




书目名称Sandostatin® in the Treatment of Acromegaly网络公开度




书目名称Sandostatin® in the Treatment of Acromegaly网络公开度学科排名




书目名称Sandostatin® in the Treatment of Acromegaly被引频次




书目名称Sandostatin® in the Treatment of Acromegaly被引频次学科排名




书目名称Sandostatin® in the Treatment of Acromegaly年度引用




书目名称Sandostatin® in the Treatment of Acromegaly年度引用学科排名




书目名称Sandostatin® in the Treatment of Acromegaly读者反馈




书目名称Sandostatin® in the Treatment of Acromegaly读者反馈学科排名

embolus

Medical Treatment of Acromegaly. Dopaminergic Agonists and Long-Acting Somatostatin,The medical treatment of acromegaly is of value because neurosurgery and Rx therapy may be unsuccessful in this disease.

Eeg332

,Experience with Sandostatin® in Various Groups of Acromegalic Patients,The availability, for clinical use, of the somatostatin analogue SMS 201–995 (Sandostatin.) has opened new doors in the treatment of acromegaly [1, 5, 6]. We report here our experience with Sandostatin used either as a chronic medical therapy or as a preparation to surgery.

Madrigal

,Treatment of Acromegaly with SMS 201–995 (Sandostatin®): Clinical, Biochemical and Morphologic StudCurrent therapy of acromegaly is unsatisfactory, and in a significant proportion of acromegalic patients the disease remains clinically active after all approved therapeutic modalities (surgery, irradiation and bromocriptine) have been exhausted.

Synchronism

屈尊

headlong

https://doi.org/10.1007/978-3-642-73694-0cardiovascular; cardiovascular disease; clinical trial; dopamine; growth; growth hormone; hormone; hyperten

spinal-stenosis

,Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995 (Sandostatin®),ts efficacy and long-term usefulness in 12 patients with therapy-resistant disease. All had been previously treated by transsphenoidal surgery, irradiation, bromocriptine or a combination of these but their GH concentrations had been insufficiently lowered. Duration of Sandostatin treatment was at least 12 months in all patients.

manifestation

,Observations During a Clinical Trial of Sandostatin® in Acromegalic Patients,viously untreated or had been unsuccessfully treated with bromocriptine. At entrance to the study they had 24-h serum growth hormone means ranging from 19.4 to 154 ng/ml and pronounced clinical evidence of active acromegaly.

Evacuate